OncoTherapy Science, Inc. (JP:4564)

:4564

4564

OncoTherapy Science

RESEARCH TOOLSreports

OncoTherapy Science (4564) Price & Analysis

Compare

2 Followers

4564 Stock Chart & Stats

¥21.00

-¥1.00(-4.17%)

At close: Jan 08 4:00 PM EST

¥21.00

-¥1.00(-4.17%)

Day’s Range― - ―

52-Week Range¥19.00 - ¥35.00

Previous CloseN/A

Volume4.29M

Average Volume (3M)39.41M

Market Cap

¥8.44B

Enterprise Value¥5.38B

Total Cash (Recent Filing)¥1.23B

Total Debt (Recent Filing)¥37.14M

Price to Earnings (P/E)―

Beta0.42

Next Earnings

Jan 29, 2027

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.63

Shares Outstanding383,643,700

10 Day Avg. Volume60,218,049

30 Day Avg. Volume39,409,347

Financial Highlights & Ratios

PEG Ratio0.19

Price to Book (P/B)10.03

Price to Sales (P/S)9.75

P/FCF Ratio-8.97

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Oncology-focused R&DOncoTherapy's specialization in cancer genomics and molecular-targeted therapies places it squarely in a structurally growing oncology sector with persistent unmet needs. This scientific focus creates high technical barriers to entry, supports durable pipeline value and long-term partnership interest beyond short-term cycles.

Revenue & EPS Growth TrendReported mid-teens revenue growth and notable EPS improvement imply improving commercial or operational momentum despite overall losses. Sustained top-line and EPS progression over months can validate program advances or better cost absorption, strengthening strategic options like partnerships or milestone-based financing.

Equity-funded Balance Sheet BufferA relatively high equity ratio gives OncoTherapy a capital cushion versus peers with heavier leverage, reducing immediate insolvency risk and preserving flexibility. For a cash-burning biotech, equity strength supports R&D continuity and bargaining power in licensing or fundraising over the medium term.

Bears Say

Persistent Negative Cash FlowThe company reports sustained negative operating and free cash flows and dependence on financing to sustain operations. Over a 2-6 month horizon this raises runway and dilution risk, constrains strategic flexibility, and makes execution contingent on external capital markets or deal-driven financing.

Structural UnprofitabilityConsistent negative gross, net and operating margins point to structural unprofitability rather than temporary weakness. Without clear margin inflection from commercial traction or cost discipline, the company must rely on recurring external funding, increasing long-term execution risk for its clinical and development programs.

Eroding Equity & Meaningful LiabilitiesA trend of declining total assets and stockholders' equity combined with meaningful liabilities indicates capital erosion and limited financial headroom. This reduces resilience to shocks, heightens refinancing risk, and may limit the company's ability to invest in R&D or pursue M&A without dilutive or costly financing.

4564 FAQ

What was OncoTherapy Science, Inc.’s price range in the past 12 months?

OncoTherapy Science, Inc. lowest stock price was ¥19.00 and its highest was ¥35.00 in the past 12 months.

What is OncoTherapy Science, Inc.’s market cap?

OncoTherapy Science, Inc.’s market cap is ¥8.44B.

When is OncoTherapy Science, Inc.’s upcoming earnings report date?

OncoTherapy Science, Inc.’s upcoming earnings report date is Jan 29, 2027 which is in 306 days.

How were OncoTherapy Science, Inc.’s earnings last quarter?

OncoTherapy Science, Inc. released its earnings results on Feb 06, 2026. The company reported -¥0.63 earnings per share for the quarter, missing the consensus estimate of N/A by -¥0.63.

Is OncoTherapy Science, Inc. overvalued?

According to Wall Street analysts OncoTherapy Science, Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does OncoTherapy Science, Inc. pay dividends?

OncoTherapy Science, Inc. does not currently pay dividends.

What is OncoTherapy Science, Inc.’s EPS estimate?

OncoTherapy Science, Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does OncoTherapy Science, Inc. have?

OncoTherapy Science, Inc. has 383,643,700 shares outstanding.

What happened to OncoTherapy Science, Inc.’s price movement after its last earnings report?

OncoTherapy Science, Inc. reported an EPS of -¥0.63 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of OncoTherapy Science, Inc.?

Currently, no hedge funds are holding shares in JP:4564

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

OncoTherapy Science, Inc.

OncoTherapy Science, Inc. researches and develops anti-cancer medicines and therapies in Japan. Its clinical development product pipeline includes small-molecule drugs, such as OTS167, a maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I clinical trials for the treatment of breast cancer; and OTS964, a T-LAK cell-originated protein kinase inhibitor for the treatment of various cancer diseases. The company's clinical development product pipeline also comprise cancer- specific peptide vaccines, including S-588410, which is in Phase III clinical trials for the treatment esophageal cancer, as well as in Phase II clinical trials for the treatment of bladder cancer; S-488210 that is in Phase I/II clinical trials for the treatment of head and neck cancer; and S-588210, which is in Phase I clinical trials for the treatment of solid tumor. In addition, it is developing antibody drugs consisting of OTSA101, which is in Phase I clinical trials for synovial sarcoma; and KHK6640, an anti-amyloid beta peptide antibody that is Phase I clinical trials for Alzheimer's disease. Further, the company provides contract analysis services. OncoTherapy Science, Inc. was founded in 2001 and is headquartered in Kawasaki, Japan.